Japan’s Astellas Reaches Patent Agreement With Taiyo On Cefdinir
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Astellas Pharma announced it has reached a settlement agreement with Nagoya-based Taiyo Yakuhin over antibiotic drug Cefzon (cefdinir). Taiyo manufactured and marketed generic products of cefdinir that violated Astellas's patent, according to the company. Taiyo agreed to pay an undisclosed settlement amount to Astellas. (Click here for more - Japanese language